舒泰神(300204.SZ):複方聚乙二醇(3350)電解質口服溶液獲批上市
格隆匯9月26日丨舒泰神(300204.SZ)公佈,公司近日收到國家藥監局核准簽發的複方聚乙二醇(3350)電解質口服溶液《藥品註冊證書》,取得了該藥品生產的註冊批件。
舒泰清(通用名:複方聚乙二醇電解質散(IV);劑型:散劑)是公司主要產品之一。舒泰清的適應症為“用於治療功能性便祕;用於術前腸道清潔準備,腸鏡及其它檢查前的腸道清潔準備。”舒泰清為患者帶來了符合國際“清腸、治療便祕金標準”的藥物,成為《中國消化內鏡診療腸道準備指南》和《中國慢性便祕診治指南》的一線用藥,市場份額在國內領先。
舒泰清列入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2009年版)》,類別為乙類藥品,2017年和2021年再次列入《國家醫保藥品目錄》。除西藏以外,銷售區域覆蓋全國。
舒泰清市場銷售情況良好,自2004年上市以來一直保持着高速增長。2021年舒泰清銷售收入為3.98億元,佔營業收入的68.19%,較去年同期增長39.09%。
複方聚乙二醇(3350)電解質口服溶液是公司持續豐富全球治療便祕金標準藥物—聚乙二醇類產品線的又一力作,適應症為治療慢性便祕,註冊分類為化學藥品3類,劑型為口服溶液劑。
複方聚乙二醇(3350)電解質口服溶液的原研製劑為英國Norgine公司生產的MOVICOL Ready To Take Sachet,自2016年在英國獲批上市後,先後在芬蘭、德國、愛爾蘭、意大利、葡萄牙、西班牙等多個國家獲得了批准。公司該次項目的研發成功將填補我國國產聚乙二醇(3350)類藥品市場的空白,國內目前尚無同類產品上市。
複方聚乙二醇(3350)電解質口服溶液具有使用方便的特點,更具有面向廣大患者的消費可及性。該產品定位於便祕的一線治療藥物,改善便祕患者的生活質量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.